logo
Sales of Red Dye 3 Products Decline as FDA Bans More Synthetic Ingredients

Sales of Red Dye 3 Products Decline as FDA Bans More Synthetic Ingredients

Yahoo24-04-2025

The U.S. Food and Drug Administration's (FDA) decision to phase out Red Dye 3, a synthetic ingredient that gives food and beverages a vibrant red color, already appears to be altering consumer behavior: They're buying less of the stuff.
The FDA's new plan to eliminate a handful of other petroleum-based dyes by the end of 2026-including Blue Dye 1, Green Dye 3, Yellow Dye 6-is bound to put even more pressure on major manufacturers, such as PepsiCo and General Mills, to come up with innovative formulations.
Figures from NielsenIQ (NIQ), a consumer intelligence firm, show sales of products containing Red Dye 3 have declined in past years, but took a sharp tumble in January following the FDA's declaration to remove the additive from the nation's food supply.
"Whether or not this is directly correlated with the ban announcement, it appears consumers are increasingly paying attention to these ingredients-especially since we have seen sales of products with Red Dye 3 trending downward since 2023," Sherry Frey, vice president of total wellness at NIQ, told ADWEEK.
At present, food and beverage brands use synthetic dyes in thousands of products. Red Dye 40, for example, appears in nearly 24,000 items. Yellow Dye 5 exists in more than 22,000.
The artificial ingredients are most prevalent in the following categories: candy, gum, mints, snacks, desserts, beverages, and baking supplies.
"Potential fallout from the synthetic food dye ban leaves these categories vulnerable and underscores the need for an urgent response," Frey added.
In reaction to the FDA's plan to ban artificial dyes, the National Confectioners Association noted it looks forward to working on the issue with Congress and the Trump Administration. 'We are in firm agreement that science-based evaluation of food additives will help eliminate consumer confusion and rebuild trust in our national food safety system,' read a statement from the trade group, whose members include Mars, Ferrara, and Hershey's.
Why Valentine's Day May Become a Duller Shade of Red
Brands, of course, have long relied on distinct colors to attract shoppers. UPS is known for its brown trucks. Most people can identify a piece of Tiffany's jewelry by its blue box. The same strategy applies to marketing certain food and beverages.
At the same time, demand for natural ingredients is growing. Nearly 25,000 items now feature labels claiming its contents are free from artificial colors, according to NIQ, reflecting a shift in consumer preferences for cleaner food options.
"The industry has been actively moving toward artificial dye alternatives for quite some time, as consumers have increasingly been paying attention to clean label attributes," said Frey. "We anticipate consumers will respond immediately to the recent bans."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

Associated Press

time27 minutes ago

  • Associated Press

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

IBN published this article, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 5, 2025 ( NEWMEDIAWIRE ) - NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine formulation aimed at approved indications such as anesthesia and pain management. With the U.S. ketamine market valued at $750 million and global demand projected to reach $3.35 billion by 2034, the company is seeking priority review amid an ongoing national shortage. NRx also plans to petition the FDA to mandate preservative-free ketamine formulations, citing safety concerns over benzethonium chloride. This filing complements its broader strategy to expand ketamine's label to include treatment for suicidal depression, backed by clinical data from more than 1,000 patients. To view the full press release, visit About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on

3D Printing Technology Revolutionizes Breast Implants Industry - A $4.6 Billion Market by 2030
3D Printing Technology Revolutionizes Breast Implants Industry - A $4.6 Billion Market by 2030

Yahoo

time2 hours ago

  • Yahoo

3D Printing Technology Revolutionizes Breast Implants Industry - A $4.6 Billion Market by 2030

Key players like Johnson & Johnson and Establishment Labs are driving innovation with FDA-approved products. Silicone implants lead the market due to their natural feel. North America dominates in market share, fueled by high awareness and cosmetic spending. Innovative trends like 3D printing are reshaping the industry. Breast Implants Market Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Breast Implants Market - Focused Insights 2025-2030" report has been added to Breast Implants Market was valued at USD 2.98 Billion in 2024, and is projected to reach USD 4.60 Billion by 2030, rising at a CAGR of 7.5%. The global breast implants market is set to grow due to the growing popularity of anatomical breast implants and generation-to-generation development in breast implants. KEY TAKEAWAYS By Product: The silicone breast implants segment holds the largest market share, as they are highly popular for offering a natural look and feel while maintaining shape even if ruptured. By Shape: The round shape segment shows the highest of 7.70%, as they are the most preferred breast implant shape category because they offer a fuller size across the breast area and limit the rotation of implants. By Surface: In 2024, the smooth surface segment accounted for the largest market share. Smooth surface breast implants are widely used for their natural feel and movement, enhancing effectiveness and reducing the need for repeat surgeries. By Application: The breast augmentation segment accounted for the largest market share. Breast augmentation is a top cosmetic surgery worldwide, with rising demand due to cosmetic and medical needs. By End-User: The cosmetology clinics segment holds the second largest market share of over 34%, driven by specialized, well-trained, well-experienced, and experienced plastic surgeons who regularly perform breast implant procedures in cosmetology clinics. By Geography: North America dominates the global breast implants market, with over 24% share. North America's breast implant market is growing steadily due to rising awareness, high beauty care spending, and interest in advanced procedures. BREAST IMPLANTS MARKET TRENDS & DRIVERS Rapid Development in Breast Implants with 3D Printing TechnologyThe breast implant industry is rapidly evolving with advancements in development and manufacturing technologies that create significant demand for breast implants. Of such one major development is the incorporation of 3D development technologies in the manufacturing and development of breast implants. It was started in the last decade when first-in-human clinical trials of 3D-printed breast implants (2019) were started in Germany, and now it is widespread across the global market. These 3D printing and development technologies offer the highest level of customization that attracts a significant consumer base. BellaSeno is one of the German companies that uses Evonik's Resomer polymer in its Senella breast implant (3D-printed) breast scaffold products. The polymer allows the scaffold to be absorbed in the body at a rate that matches the patient's Popularity of Anatomical Breast ImplantsRound shape breast implants are considered the gold standard for breast augmentation and reconstruction; however, in recent years, the development of anatomical implants has become an exciting trend in the industry. It involves the application of custom-molded implants that are designed and developed to mimic the shape and give a natural feel. Where anatomical breast implants become an ideal choice for women who are seeking to achieve a balanced look with a natural shape. Anatomical breast implants also known as tear-drop breast implants now commonly referred to as contour profile or shaped breast implants. These implants are filled with gel which gives a more natural feel and comfort making them the most popular choice among youngsters. These increasing applications in breast enlargement to breast implant exchange become popular for patients undergoing revision breast surgery, such as those patients who demand poly implant prostheses (PIP) implant Development in Breast ImplantsThe world of breast implants has witnessed significant and continued developments. Fourth and fifth-generation breast implants revolutionized the breast implant industry. In these generations, significant changes were noticed related to silicone gel cohesivity. In 4th and 5th generation breast implants, the shell of implants was further strengthened, and cohesive versions of silicone gel were used to significantly minimize complications related to gel leakage. In 5th-generation implants, they come up with highly form-stable gel that characterizes gummy bear implants. In addition, Establishment Lab - one of the key companies in the market came up with 6th generation breast implant. The company focused on a patient-centric approach in incorporating and developing revolutionary techniques in its Motiva product to enhance both safety and aesthetic outcomes- MOTIVA IMPLANTS. It is a first-of-their-kind feature that significantly revolutionizes the Volume of Breast Enhancement ProceduresWorldwide, with the widespread of cosmetology and medical aesthetic procedures, breast augmentation procedures become the second leading surgical cosmetic procedure. According to the International Society of Aesthetic Plastic Surgery (ISAPS) report 2024, more than 1.89 million breast augmentation procedures performed across the world contribute to significant demand for breast implants. Furthermore, the ISAPS article 2024 revealed that more than 4.1 million breast procedures were reported across the world. Of these, over 1.89 million surgical breast augmentation, around 903,266 breast lifts, approx. 686,000 breast reduction, and 335,939 breast implant removal procedures reported across the world. It indicates that the demand for breast surgeries is significantly high across the BREAST IMPLANTS MARKET SEGMENT INSIGHTS Key Market Segments Product: Silicone breast implants control the largest share, emphasizing their popularity for a natural appearance. Shape: Round shapes lead with a 7.70% growth rate, preferred for full-size enhancement and reduced implant rotation. Surface: Smooth surface implants dominate due to their natural feel and reduced need for replacements. Application: Breast augmentation claims the largest application share, fueled by rising cosmetic and medical demands. Geography: North America holds a dominant market share, driven by elevated awareness and advanced procedural needs. COMPETITIVE LANDSCAPEThe global breast implants market report consists of exclusive data on 13 vendors. AbbVie, Establishment Labs, Johnson & Johnson (MENTOR), GC Aesthetics, POLYTECH Health & Aesthetics, and Tiger Biosciences are among the leading companies holding a significant market share in the global breast implants market. These vendors offer high-quality and advanced breast implant solutions that meet customer demands and comply with regulatory standards. Major players are continuously enhancing the efficiency of their products and strengthening their market positions. They benefit from strong brand recognition and a broad geographical presence across global markets. Furthermore, the adoption of various strategic initiatives, such as product launches and the development of new products with advanced technologies and materials, has intensified market competition. By focusing on innovation and expanding their capabilities, these companies have successfully increased their revenue share and maintained a competitive edge in the breast implants Strategic Approaches to Strengthen Sales Ratios In 2025, Establishment Labs developed and launched Preserve, a minimally invasive breast tissue preserving technology for breast augmentation, mastopexy augmentation, and revision augmentation procedures. In 2024, the company established a manufacturing and corporate office in Costa Rica to increase the manufacturing capacity of breast implants and other products, which will create revenue growth opportunities. In 2024, Stratasys and CollPlant announced a collaboration to conduct a pre-clinical study for advanced and unique regenerative commercial-sized breast implants. With this collaboration, the companies reported that technology innovations will address around a $3 billion market opportunity in the future. In 2023, AbbVis' Allergen Aesthetics launched the Natrelle Campaign, which will promote and create awareness about the company's breast implant solutions with a higher level of customization. In 2023, Establishment Labs Holding announced the launch of Mia Femtech, a company that offers minimally invasive breast augmentation procedures in Japan to establish a new beginning in breast aesthetics. This expansion will deliver significant brand awareness about its breast implant solution in the Asian market. Key Vendors AbbVie Establishment Labs Johnson & Johnson (MENTOR) GC Aesthetics POLYTECH Health & Aesthetics Tiger Biosciences Other Prominent Vendors Bimini Health Tech Hans Biomed Guangzhou Wanhe Plastic Material Co., Ltd G.A.L.S. Private Limited Laboratoires Arion Sebbin Silimed Key Attributes: Report Attribute Details No. of Pages 136 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.98 Billion Forecasted Market Value (USD) by 2030 $4.6 Billion Compound Annual Growth Rate 7.5% Regions Covered Global Key Topics Covered: Chapter 1: Scope & Coverage: Breast Implants Market Overview Chapter 2: Breast Implants Market Premium Insights Key Highlights Regional Insights Chapter 3: Breast Implants Market Prospects & Opportunities Chapter 4: Breast Implants Market Industry Overview Projected Revenue of Breast Implants Market (2021-2030; $ Billions) Chapter 5: Breast Implants Market Segmentation Data Projected Revenue by Product (2021-2030; $ Billions) Silicone Saline Projected Revenue by Shape (2021-2030; $ Billions) Round Anatomical Projected Revenue by Surface (2021-2030; $ Billions) Smooth Textured Projected Revenue by Application (2021-2030; $ Billions) Breast Augmentation Breast Reconstruction Projected Revenue by End-user (2021-2030; $ Billions) Hospital Cosmetology Clinics Other End-user Chapter 6: Key Regions Overview Projected Revenue of Breast Implants Market (2021-2030; $ Billions) North America Europe Latin America APAC Middle East & Africa Chapter 7: Competitive Landscape of Breast Implants Market Competitive Landscape Key Vendor Profiles Other Prominent Vendors Key Strategic Recommendations For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Breast Implants Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

New FDA-approved Alzheimer's blood test coming to Mayo Clinic
New FDA-approved Alzheimer's blood test coming to Mayo Clinic

Yahoo

time2 hours ago

  • Yahoo

New FDA-approved Alzheimer's blood test coming to Mayo Clinic

The Brief The FDA has approved the marketing of a new blood test by Fujirebio. The biomarker test measures the ratio of tau and amyloid proteins in the blood of a person with symptoms of cognitive decline to confirm the presence of Alzheimer's disease. Mayo Clinic will be one of 37 Alzheimer's clinics across the country to receive the new blood testing equipment starting at the end of June. MINNEAPOLIS (FOX 9) - The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person's blood to diagnose Alzheimer's disease. The blood test is a groundbreaking development to confirm the disease in patients who are already experiencing cognitive decline. What we know The diagnostic tool, called Lumipulse, is manufactured by the world-wide medical research and development firm Fujirebio. The procedure, called the G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test, measures the presence of the amyloid and tau proteins in the brain that build the plaques leading to Alzheimer's disease. Fujirebio will now start distributing the diagnostic tests by the end of June to 37 Alzheimer's clinics across the United States including Mayo Clinic in Rochester, Minnesota. "I was very excited to get the news that there was an FDA approved test," said Alicia Algeciras-Schimnich, Ph.D. of Mayo Clinic who's been offering a version of the blood test for the past year in their laboratory. "It's just increasing the access to patients, and now many more laboratories will be able to offer this test." Dr. Algeciras-Schimnich says Mayo hopes will have the capacity to offer 1,000 to 5,000 blood tests a month with this new diagnostic protocol. What patients say Tim Sandry admits he's never had the best memory, but when he approached turning 67, he and his wife Ellen started noticing changes. "I wanted to find out what's going on here," recalled Sandry when he and his wife decided to see a neurologist. The doctor put him through a series of cognitive tests and determined he had what's called mild cognitive impairment which is a noticeable slowing of memory function. It wasn't long after his cognitive tests that a new diagnostic spinal tap was available to detect the presence of Alzheimer's disease. But it was invasive and painful. "In the morning they took the spinal fluid, and then I had to stay very still for the rest of the day. And then they sent me home, and I had an awful headache for the next three days," said Sandry of the hospital procedure. This new test would have saved him the pain and provided reliable results. "Oh, so much difference," said Sandry about the chance to have had a diagnostic blood test. "I mean, this blood test is going to shake things up dramatically I believe." Why you should care The faster a person experiencing cognitive decline can get a positive diagnosis for Alzheimer's the faster they can start taking one of two recently FDA approved drugs to slow the progression of the disease. Those drugs are Leqembi and Kisunla. "It makes it much quicker for those people to start treatment and to start looking at what options there are, whether it's clinical trials or medication," said Jenna Fink of the Alzheimer's Association Minnesota-North Dakota chapter. Sandry has been on a regimen of Leqembi since his own diagnosis and he believes it has dramatically slowed the disease in his own brain. "The sooner you get diagnosed, the quicker you can get on those drugs and the less damage this will do to your brain And the longer you will be able to function, cognitively," he said. Dig deeper The new blood test not only speeds up the diagnosis process, it also offers more accuracy. "The clinical diagnosis of Alzheimer disease is only about 70-75% accurate," said Mayo's Alicia Algeciras-Schimnich of the standard practice of cognitive testing and PET scans of the brain. Adding the blood biomarker test increases the accuracy of an Alzheimer's diagnosis to 90-95%. "So really, it is a significant improvement in the diagnosis for patients, which now can have an earlier answer for their symptoms," said Algeciras-Schmnich.' By the numbers As many as 101,900 Minnesotan over the age of 65 are living with Alzheimer's according to the 2025 facts and figures report from the Alzheimer's Association. That adds up to 10.7% of Minnesota adults over 65. Alzheimer's affects more than just the patients. For every patient, there are caregivers, many of them family members. When those numbers are added up, the Alzheimer's Association estimates there are 166,000 caregivers in Minnesota. Across the nation, 7.2 million Americans are living with the Alzheimer's, and 74% are over the age of 75.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store